PAVmed Earnings Call Transcripts
Fiscal Year 2026
-
Progress across all business segments, with Lucid advancing reimbursement, Veris accelerating commercial rollout at OSU, and PortIO achieving positive clinical results. Q2 GAAP net loss was $5.5M, with cash at $3.8M and significant financing activities completed.
-
Restructuring completed, simplifying capital structure and enabling growth across diversified life sciences segments. Lucid and Veris subsidiaries are advancing toward key milestones, with Lucid nearing Medicare coverage and Veris expanding its commercial rollout.
Fiscal Year 2025
-
Completed major restructuring and recapitalization, positioning for growth with a clean balance sheet and expanded MedTech portfolio. Lucid and Veris segments showed strong operational progress, with Lucid's revenue and test volumes up and Veris advancing its implantable device.
-
Stabilized structure and balance sheet through debt restructuring and subsidiary deconsolidation. Main subsidiaries advanced key milestones: Lucid neared Medicare coverage and raised $27M, while Veris launched a major partnership and progressed its implantable device toward FDA submission.
-
Q2 revenue grew 40% sequentially to $1.2M, with test volumes in target range and a strengthened cash position. Medicare coverage is seen as imminent, with a key CAC meeting in September and a robust commercial pipeline. Highmark Blue Cross Blue Shield coverage and scalable operations support future growth.
-
Stabilized structure and strong cash positions enable subsidiaries to advance key milestones, with Lucid nearing Medicare coverage and Veris securing a major partnership. Financials reflect positive net income, reduced debt, and continued access to capital.
Fiscal Year 2024
-
Strategic restructuring and deconsolidation actions have positioned the company for long-term stability and growth. Lucid Diagnostics and Veris Health achieved strong revenue and operational milestones, while new financing and partnerships support continued advancement of key assets.
-
Strategic transformation completed with Lucid deconsolidation and debt restructuring, resulting in a $61M GAAP net income and record revenue at Lucid Diagnostics. Subsidiaries are advancing with new funding, successful pilots, and expanded market initiatives.
-
Subsidiaries are advancing toward independent financing, with Lucid Diagnostics showing record test volume growth and Veris Health progressing on its pilot and implantable monitor. Revenue was flat sequentially but up sixfold year-over-year, with ongoing efforts to improve reimbursement and secure funding for future operations.